Related Experiment Video
Updated: Mar 13, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Breath restored: yoga-based training lowers estimated lung age among individuals with opium dependence in a
Arjun Ram Roj1, Surajnath Siddh2, Harish Sharma1
1Department of Yoga, Central University of Rajasthan, Ajmer, India.
Background:
Chronic opium use is associated with respiratory impairment and increased risk of respiratory-related mortality. We evaluated whether a structured, breath-centred yoga programme could improve pulmonary function in men with opium dependence.
Methods:
In this single-arm pre-post feasibility study, 38 men were enrolled during a 1-month residential de-addiction programme and 30 completers (mean age 43.5 ± 12.2 years) underwent spirometry at baseline and after a month of twice-daily, instructor-led breath-based yoga (pranayama, asana-linked breathing, and relaxation). Primary outcomes were within-group changes in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC, peak expiratory flow rate (PEFR), mid-expiratory flows, and estimated lung age; paired t-tests and Cohen's d were used for inference.
Results:
The intervention was associated with statistically significant increases in FVC (2.76 ± 0.94 to 3.37 ± 0.73 L; mean change +0.61 L; p < 0.001; d = 0.88) and PEFR (4.45 ± 1.95 to 6.09 ± 1.97 L·s-¹; +1.64; p < 0.001; d = 0.84), and a moderate increase in FEV1 (2.34 ± 0.88 to 2.71 ± 0.79 L; +0.37; p = 0.011; d = 0.49). FEV1/FVC did not change significantly (85.65 ± 9.41% to 82.15 ± 17.55%; p = 0.404). Estimated lung age decreased by a mean of 6.72 years (47.96 ± 16.87 to 41.24 ± 14.00 years; p = 0.003; d = 0.59). No serious adverse events were reported.
Conclusions:
A month of structured breath-based yoga produced clinically and statistically meaningful improvements in lung volumes, expiratory flow, and estimated lung age in men with chronic opium dependence. These pilot data support testing this culturally acceptable, low-cost intervention in larger, randomized trials to confirm efficacy, explore mechanisms, and determine durability.
Trial Registration:
CTRI/2025/07/089999.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Lung Capacity

